Review of the Proceedings of the European Society for Medical Oncology (ESMO) 2017 Congress
| Autor: | A. A. Kirichek, B. Sh. Kamolov, V. B. Matveev |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
lenvatinib in combination with pembrolizumab
whole exome sequencing of tumor dna ramucirumab Urology sequential targeted therapy combination immunotherapy with nivolumab and ipilimumab Library science monoclonal antibody vegfr-2 antagonist tumor mutation burden Clinical Practice Oncology cabozantinib Nephrology General partnership Political science Medicine Radiology Nuclear Medicine and imaging Surgery deferred cytoreductive nephrectomy |
| Zdroj: | Onkourologiâ, Vol 13, Iss 4, Pp 133-140 (2018) |
| ISSN: | 1996-1812 1726-9776 |
| DOI: | 10.17650/1726-9776-2017-13-4-133-140 |
| Popis: | The European Society for Medical Oncology (ESMO) Congress in partnership with the European Association for Cancer Research took place between September 8th and 12th of 2017 in Madrid. In 42 years of its existence, the forum has grown from a regional educational meeting in Europe to the main international event in oncology. The key topic of this Congress was integration of molecular biology knowledge with clinical specialties. The ESMO 2017 Congress united almost 24,000 professionals of various fields from 131 countries who submitted 1736 abstracts. More than 50 scientific abstracts which were deemed worthy of special discussion and capable of changing current clinical practice, were separated into a category of late-breaking abstract (LBA). This review highlights some important topics of oncological urology that were discussed at the ESMO 2017 Congress. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|